Reports Q1 revenue $737.8M, consensus $726.89M. “We are pleased with our solid start to 2024,” said CEO Liam Kelly. “In the quarter, we drove strong execution with constant currency growth and margin expansion year-over-year, executed against our new product launch objectives, and remained on track with our integration of Palette Life Sciences AB. Our Q1 performance, combined with an improving macro-environment, keeps us well-positioned to deliver on our financial guidance for 2024.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
- Teleflex Announces the Limited Market Release of the Wattson™ Temporary Pacing Guidewire
- Teleflex to Present at the BofA Securities 2024 Health Care Conference
- Teleflex Announces First Quarter 2024 Earnings Conference Call Information
- Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types